Please login to the form below

Not currently logged in
Email:
Password:

Zealand Pharma

This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to

Latest news

  • Sanofi uses priority review voucher for diabetes combo Sanofi uses priority review voucher for diabetes combo

    The French pharma group paid $245m for the voucher - which cuts four months of the FDA's usual review time - in a deal with Retrophin earlier this year. ... Lixisenatide is a once-daily GLP-1 agonist that was invented by Zealand Pharma and has been sold

  • Boehringer switches diabetes candidate in Zealand collaboration Boehringer switches diabetes candidate in Zealand collaboration

    Boehringer Ingelheim has decided to drop the diabetes and obesity drug candidate ZP2929 it has spent nearly three years developing with Zealand Pharma. ... Zealand Pharma said potential choices include medicines that require once-weekly dosing, something

  • Sanofi receives EU approvals for diabetes and cancer drugs Sanofi receives EU approvals for diabetes and cancer drugs

    Lyxumia's approval is good news too for the drug's inventors Zealand Pharma who signed a deal with Sanofi to further develop the drug. ... Zealand also said it is eligible to receive remaining development, regulatory and sales milestone payments of up to

  • Pharma deals for May 2012 Pharma deals for May 2012

    As often can be the case, another thread to this deal was Action Pharma's existing relationship with Zealand Pharma: AP214 was developed utilising technology Action had in-licensed from Zealand. ... In turn, Action will make a one-off payment of $11m to

  • Hybrigenics appoints Dr Alain Munoz

    As well as his position at Hybrigenics, Dr Munoz is also a board member of several biotechnology companies including Novagali Pharma and Zealand Pharma.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.

  • Bionor names executive management team additions Bionor names executive management team additions

    He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has

  • Zealand announces management changes Zealand announces management changes

    Zealand announces management changes. Firm making the roles of chief scientific officer and chief operating officer redundant. ... Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.

  • Zealand's Arvind Hundal steps down as chief business officer Zealand's Arvind Hundal steps down as chief business officer

    Zealand's Arvind Hundal steps down as chief business officer. She leaves after five years with the Danish biotech company. ... Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics